Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Payables: 2020-2025

Historic Payables for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $2.2 million.

  • Tango Therapeutics' Payables fell 45.79% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 18.39%. This contributed to the annual value of $1.6 million for FY2024, which is 42.51% down from last year.
  • According to the latest figures from Q3 2025, Tango Therapeutics' Payables is $2.2 million, which was down 14.50% from $2.6 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Payables high stood at $6.3 million for Q3 2022, and its period low was $26,279 during Q2 2021.
  • For the 3-year period, Tango Therapeutics' Payables averaged around $3.2 million, with its median value being $2.8 million (2023).
  • Its Payables has fluctuated over the past 5 years, first surged by 60,093.61% in 2021, then tumbled by 77.84% in 2024.
  • Tango Therapeutics' Payables (Quarterly) stood at $3.2 million in 2021, then skyrocketed by 38.03% to $4.5 million in 2022, then plummeted by 37.46% to $2.8 million in 2023, then crashed by 42.51% to $1.6 million in 2024, then plummeted by 45.79% to $2.2 million in 2025.
  • Its Payables stands at $2.2 million for Q3 2025, versus $2.6 million for Q2 2025 and $3.2 million for Q1 2025.